Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study
Francelise Bridi Cavassin,Marcello Mihailenko Chaves Magri,Jose Ernesto Vidal,Fabianne Altruda de Moraes Costa Carlesse,Diego Rodrigues Falci,João Luís Baú-Carneiro,Giovanni Luís Breda,Fábio de Araújo Motta,Cássia Silva de Miranda Godoy,Renata de Bastos Ascenço Soares,Carla Sakuma De Oliveira,Ana Verena Almeida Mendes,Hugo Paz Morales,Patrícia Silva Montes,Mariane Taborda,Caroline Martins Rego,Maíra Araujo Félix,Paula Pacheco Katopodis,Julia Raquel da Silva do Ó,Mirela Pereira Lima Abrão,Talita Teles Teixeira Pereira,Flávio Queiroz-Telles
DOI: https://doi.org/10.1016/j.clinthera.2024.01.011
IF: 3.637
2024-02-26
Clinical Therapeutics
Abstract:Purpose Data on the real-life use of amphotericin B lipid complex (ABLC) compared with other available formulations are limited. This study aimed to evaluate the effectiveness, tolerability, and safety of different amphotericin B (AMB) intravenously administered in the context of hospital practice for the treatment of invasive fungal infections (IFI) and to provide new insights into the profile of ABLC. Methods This is a multicenter, retrospective, observational study conducted at 10 tertiary Brazilian hospitals. Patients first exposed to any formulation of AMB for treating endemic and opportunistic IFI who had received at least 2 intravenous doses were screened. Retrospective data (from January 2014 to December 2019) were extracted from the patients' medical records. Clinical parameters were examined pre- and post-treatment to determine effectiveness; acute infusion-related side effects (IRSE) and drug interruption to determine tolerability; and adverse events, toxicity, and treatment interruption were stated to analyze safety. Findings Overall, 1879 medical records of patients were identified. The median (interquartile rate) duration of treatment was 14 (7–21) days. The overall success rate (95% confidence interval [CI]) was 65% (95% CI 60–65). ABLC proved to be effective among AMB formulations with 59% (95% CI 55.6–62.5) within complete response. This was significantly higher in patients who received the drug for a longer period, ≥4 weeks compared to <1 week treatment ( P < 0.001). IRSE was observed in 446 (23.7%) patients. Eight cases (1.4%) of severe IRSE in pediatrics and 14 (1.1%) in adults resulted in treatment discontinuation. Regarding safety, 637 (33.9%) patients presented some alteration in creatinine levels during AMB exposure, and 89 (4.74%) had to interrupt or discontinue the drug within the first 14 days of therapy because of renal dysfunction. Overall mortality was 34%. Implications ABLC is an effective formulation for the treatment of invasive fungal infections, with few adverse events leading to drug discontinuation or lethal outcomes. Furthermore, this real-life study confirmed the comparative safety of AMB lipid formulations versus AMB deoxycholate.
pharmacology & pharmacy